VEGFA and neoplasm: The second-generation IMiD, lenalidomide, inhibits the VEGF-induced PI3K-Akt signaling pathway (Figure 3) and HIF-1 expression [148], induces apoptosis of tumor cells, blocks the activity of TNF, and modulates T cells and NK cells activities [149,150,151,152,153].